ARCHIVES

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

DeVita, Seffrin Present Cancer Czar PlanTo Feinstein, Without Committee Sign-Off

June 1, 2001

Final Issue of the Year

December 13, 1985

FDA Approves Imaging Agent For Recurrent Prostate Cancer

September 28, 2012

Herceptin Regimen Minus Adriamycin Increases Survival With Less Toxicity

October 28, 2011

Virus Studies Approved By DCE Board for $2.5 Mil. In First Year

November 3, 1989

ASCO, NCCN Develop Quality Measures For Cancer Care

August 25, 2006